Effects of two different units of botulinum toxin type a evaluated by computed tomography and electromyographic measurements of human masseter muscle

Plastic and Reconstructive Surgery

Volumn 119, Issue 2, 2007, Pages 711-717

  Kim, Jae Hong ^a   Shin, Jun Han ^a   Kim, Seong Taek ^a   Kim, Chong Youl ^a  

^a Yonsei University College of Dentistry   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; ELECTROMYOGRAPHY; FEMALE; HUMAN; MALE; MASSETER MUSCLE; MUSCLE HYPERTROPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; BOTULINUM TOXIN TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROMYOGRAPHY; FEMALE; HUMANS; HYPERTROPHY; MALE; MASSETER MUSCLE; NEUROMUSCULAR AGENTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33846418749     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.prs.0000239453.67423.99     Document Type: Article

References (35)

1. Legg, J. W. Enlargement of the temporal and masseter muscles on both sides. Trans. Pathol. Soc. Lond. 31: 361, 1880.
2. Gurney, C. E. Chronic bilateral benign hypertrophy of the masseter muscles. Am. J. Surg. 73: 137, 1947.
3. Beckers, H. L. Masseteric muscle hypertrophy and its intraoral surgical correction. J. Maxillofac. Surg. 5: 28, 1977.
4. Nishioka, G. J., and Montgomery, M. T. Masticatory muscle hyperactivity in temporomandibular disorders: Is it an extrapyramidally expressed disorder? J. Am. Dent. Assoc. 116: 514, 1988.
5. Bertram, S., Rudisch, A., Bodner, G., and Emshoff, R. The short-term effect of stabilization-type splints on the local asymmetry of masseter muscle sites. J. Oral Rehabil. 28: 1139, 2001.
6. Bertram, S., Rudisch, A., Bodner, G., and Emshoff, R. Effect of stabilization-type splints on the asymmetry of masseter muscle sites during maximal clenching. J. Oral Rehabil. 29: 447, 2002.
7. Scott, A. B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 87: 1044, 1980.
8. Klein, A. W. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol. Surg. 29: 549, 2003.
9. Wheeler, A. H. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache 38: 468, 1998.
10. Freund, B. J., and Schwartz, M. Treatment of whiplash associated neck pain with botulinum toxin-A: A pilot study. J. Rheumatol. 27: 481, 2000.
11. Acquadro, M. A., and Borodic, G. E. Treatment of myofascial pain with botulinum A toxin. Anesthesiology 80: 705, 1994.
12. Cheshire, W. P., Abashian, S. W., and Mann, J. D. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 59: 65, 1994.
13. Silberstein, S., Mathew, N., Saper, J., and Jenkins, S. Botulinum toxin type A as a migraine preventive treatment. Headache 40: 445, 2000.
14. Moyer, R. E. Temporomandibular muscle contraction patterns in Angle class II division 1 malocclusion: An electromyographic study. Am. J. Orthod. Dentofac. Orthop. 35: 836, 1949.
15. Mohl, N. D., Lund, J. P., Widmer, C. G., and McCall, W. D., Jr. Devices for the diagnosis and treatment of temporomandibular disorders: Part II. Electromyography and sonography. J. Prosthet. Dent. 63: 332, 1990.
16. Ramfjord, S. P. Bruxism, a clinical and electromyographic study. J. Am. Dent. Assoc. 62: 21, 1961.
17. Kawazoe, Y., Kotani, H., and Hamada, T. Relation between integrated electromyographic activity and biting force during voluntary isometric contraction in human masticatory muscles. J. Dent. Res. 58: 1440, 1979.
18. Manns, A., Miralles, R., Santander, H., and Valdivia, J. Influence of the vertical dimension in the treatment of myofascial pain dysfunction syndrome. J. Prosthet. Dent. 50: 700, 1983.
19. Ingervall, B., and Carlsson, G. E. Masticatory muscle activity before and after elimination of balancing side occlusal interference. J. Oral Rehabil. 9: 183, 1982.
20. Moore, A. P., and Wood, G. D. The medical management of masseteric hypertrophy with botulinum toxin type A. Br. J. Oral Maxillofac. Surg. 32: 26, 1994.
21. Smyth, A. G. Botulinum toxin treatment of bilateral masseteric hypertrophy. Br. J. Oral Maxillofac. Surg. 32: 29, 1994.
22. von Lindern, J. J., Niederhagen, B., Appel, T., Berge, S., and Reich, R. H. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: An alternative treatment. Plast. Reconstr. Surg. 107: 327, 2001.
23. Kim, H. J., Yum, K. W., Lee, S. S., Heo, M. S., and Seo, K. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol. Surg. 29: 484, 2003.
24. Park, M. Y., Ahn, K. Y., and Jung, D. S. Botulinum toxin type A treatment for contouring of the lower face. Dermatol. Surg. 29: 477, 2003.
25. To, E. W. H., Ahuja, A. T., Ho, W. S., et al. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br. J. Plast. Surg. 54: 197, 2001.
26. Borodic, G. E., Ferrante, R., Pearce, L. B., and Smith, K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov. Disord. 9: 31, 1994.
27. Shaari, C. M., and Sanders, I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve 16: 964, 1993.
28. Borodic, G. E., and Ferrante, R. Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J. Clin. Neuroophthalmol. 12: 121, 1992.
29. Lew, M. F., Adornato, B. T., Duane, D. D., et al. Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49: 701, 1997.
30. Atassi, M. Z., and Oshima, M. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit. Rev. Immunol. 19: 219, 1999.
31. Greene, P., Fahn, S., and Diamond, B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov. Disord. 9: 213, 1994.
32. Oshima, M., Middlebrook, J. L., and Atassi, M. Z. Antibodies and T cells against synthetic peptides of the C-terminal domain (Hc) of botulinum neurotoxin type A and their cross-reaction with Hc. Immunol. Lett. 60: 7, 1998.
33. Brin, M. F. Botulinum toxin therapy: Basic science and overview of other therapeutic applications. In A. Blitzer, W. J. Binder, J. B. Boyd, and A. Carruthers (Eds.), Management of Facial Lines and Wrinkles. Philadelphia: Lippincott Williams & Wilkins, 2000. Pp. 279-302.
34. dePaiva, A., Meunier, F. A., Molgo, J., et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl. Acad. Sci. U.S.A. 96: 3200, 1999.
35. Blitzer, A., and Sulica, L. Botulinum toxin: Basic science and clinical uses in otolaryngology. Laryngoscope 111: 218, 2001.